FDA Rejects Bidi Vapor's Bidi Stick Classic Market Application, Again

Regulations by 2FIRSTS.ai
FDA Rejects Bidi Vapor's Bidi Stick Classic Market Application, Again
US FDA rejects Bidi Vapor LLC's application for marketing Bidi Stick Classic e-cigarette, prohibiting its sale or distribution in the US.

According to a report by journalnow on January 22, the US Food and Drug Administration (FDA) has rejected Bidi Vapor LLC's market application for the Bidi Stick Classic e-cigarette.


After the FDA issued a marketing denial order, Bidi vapour company has been prohibited from selling or distributing its product in the US market, otherwise it will face enforcement actions from the FDA. However, Bidi vapour company has the right to submit a new marketing application to the FDA.


According to the FDA's requirements, e-cigarette manufacturers must prove that their products not only serve as a reduced-risk alternative for adult smokers but also ensure that the transition to their products does not result in the illegal use of these products by individuals under the age of 21. However, the FDA believes that Bidi Vapor Company has failed to meet these evidentiary requirements.


This article is translated from an original Chinese article available on 2firsts.cn by AI, and has been reviewed and edited by 2FIRSTS's English editorial team. The Chinese original text is the only authoritative source of information. The exclusive copyright and license rights to this article are held by 2FIRSTS Technology Co., Ltd. Any reproduction, reprinting, or redistribution of this article, either in part or in full, requires express written permission from 2FIRSTS and must include clear attribution along with a link to this content. Non-compliance may result in legal action. 2FIRSTS Technology Co., Ltd. reserves the right to pursue legal actions in case of unauthorized use or distribution.